PA-SYNERGIS-SOFTWARE
24.3.2022 13:23:11 CET | Business Wire | Press release
Synergis Software , a global leader in engineering document management and workflow solutions, announced today that Synergis Adept was named as a Leader in the Enterprise Content Management and Product Data Management categories in the G2 Spring 2022 Grid® Reports. G2 is a peer-to-peer business software review website that helps companies choose the best tools for their business. Products in the Leader quadrant are rated highly by verified users of the software product and have significant market presence scores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005238/en/
According to G2’s 2022 Spring Reports, Adept software earned 18 G2 Badges with top placements for “Best Usability”, “Fastest Implementation”, “Ease of Setup”, “Ease of Admin”, and “Highest User Adoption”, and grade the company as “Easiest to do Business With” and “Best Support”—recognition Synergis has received consistently over the past seven quarters.
“These achievements reflect the experience we deliver with our software and the relationships we build with some of the world’s best companies,” says Scott Lamond, vice president of marketing at Synergis Software. “Delivering value in ways that are meaningful to our customers is our top priority, so the G2 results really matter to us. Our customers range from small to very large across varied industries , and they’re all part of the Synergis family. We’re grateful for their trust and inspired to bring them even greater value as we grow together.”
G2 highlights the value of Adept engineering document management software across three categories: Enterprise Content Management, Product Data Management, and Construction Drawing Management. G2 Spring 2022 badges include:
- Leader Enterprise Content Management (ECM)
- Leader Product Data Management (PDM)
- Momentum Leader Enterprise Content Management (ECM)
- Momentum Leader Product Data Management (PDM)
- High Performer Mid-Market Enterprise Content Management (ECM)
- High Performer Mid-Market Product Data Management (PDM)
- High Performer Construction Management
- High Performer Construction Drawing Management
- Best Relationship
- Best Support
- Best Support Small-Business
- Easiest To Do Business With Mid-Market
- Easiest To Do Business With
- Easiest To Do Business With Small-Business
- Fastest Implementation
- Highest User Adoption
- Most Implementable
- Best Usability
The G2 reports are based on direct customer feedback combined with G2’s unique algorithm that calculates customer satisfaction and market presence scores in real-time.
For more details about Adept in the G2 Spring 2022 Reports, visit our website .
Quotes from Verified Users about Synergis Adept
“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites."
Teresa Yang, Product Manager, Document Management, Dow Chemical
“No other software company anywhere works as closely with their customers. The staff is incredibly responsive and consistently goes above and beyond to solve customer issues. For a system your business cannot operate without, this is invaluable.”
Ryan Mongeau, Director of Technology, Space Age Electronics
“Adept has improved our efficiency/processes by 200%. What once took hours in the old systems, I can do in minutes. It’s a very powerful system with unlimited possibilities for adding more useful information for future projects. And the Helpdesk team can tackle and/or resolve any issue I bring to them to improve or streamline our processes.”
Milias H, The Folger Company, Document Control Service Provider
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded.
Adept has been battle tested by engineers for over 30 years with customers such as Dow Chemical, Con Edison, General Mills, Merck, NASA, and Nucor Steel.
About G2 Crowd
G2 is the world’s largest tech marketplace where businesses can discover, review, and manage the technology they need to reach their potential. Today, more than 3M people visit G2 to read and write authentic reviews about thousands of software products and professional services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005238/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom